Omeros Corp OMER:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:27 PM EDT
3.80quote price arrow up+0.07 (+1.88%)
Volume
3,956
Close
3.73quote price arrow up+0.01 (+0.27%)
Volume
154,865
52 week range
0.92 - 7.80
Loading...
  • Open3.76
  • Day High3.84
  • Day Low3.61
  • Prev Close3.72
  • 52 Week High7.80
  • 52 Week High Date06/05/23
  • 52 Week Low0.92
  • 52 Week Low Date10/16/23

Key Stats

  • Market Cap216.126M
  • Shares Out57.94M
  • 10 Day Average Volume0.25M
  • Dividend-
  • Dividend Yield-
  • Beta1.35
  • YTD % Change14.07

KEY STATS

  • Open3.76
  • Day High3.84
  • Day Low3.61
  • Prev Close3.72
  • 52 Week High7.80
  • 52 Week High Date06/05/23
  • 52 Week Low0.92
  • 52 Week Low Date10/16/23
  • Market Cap216.126M
  • Shares Out57.94M
  • 10 Day Average Volume0.25M
  • Dividend-
  • Dividend Yield-
  • Beta1.35
  • YTD % Change14.07

RATIOS/PROFITABILITY

  • EPS (TTM)-2.79
  • P/E (TTM)-1.34
  • Fwd P/E (NTM)-1.65
  • EBITDA (TTM)-163.61M
  • ROE (TTM)-576.33%
  • Revenue (TTM)-
  • Gross Margin (TTM)98.89%
  • Net Margin (TTM)-136.61%
  • Debt To Equity (MRQ)-1,354.04%

EVENTS

  • Earnings Date05/07/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Omeros Corp

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for...
Gregory Demopulos M.D.
Chairman of the Board, President, Chief Executive Officer
Michael Jacobsen
Vice President - Finance, Chief Accounting Officer, Treasurer
Peter Cancelmo J.D.
Vice President, General Counsel, Secretary
Mariana Dimitrova Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Tina Quinton J.D.
Vice President - Patents
Address
201 Elliott Avenue West
Seattle, WA
98119
United States

Top Peers

SYMBOLLASTCHG%CHG
SCPH
scPharmaceuticals Inc
4.66UNCHUNCH
MDWD
Mediwound Ltd
18.65-0.19-1.01%
RLMD
Relmada Therapeutics Inc
3.68-0.04-1.08%
HRBR
Harbor Diversified Inc
1.77-0.01-0.56%
CRMD
CorMedix Inc
5.84+0.47+8.75%